Somatic GNAQ mutations at codon 209 have been identified in approximately 50% of uveal melanomas (UM) and have been reported to be oncogenic through activating PLCβ-PKC-Erk1/2 pathways. We hypothesized that PKC may provide new opportunities for therapeutic targeting of UM carrying GNAQ mutations. To test this hypothesis, UM cells harboring wild type or mutant GNAQ were treated with the PKC inhibitor AEB071 (sotrastaurin) or infected with lentivirus expressing shRNAs targeting PKC isoforms. Notably, AEB071 at low micromolar concentrations significantly inhibited the growth of UM cells harboring GNAQ mutations through induction of G1 arrest and apoptosis. However, AEB071 had little effect on UM cells carrying wild type GNAQ. AEB071-mediated cell inhibition in the GNAQ mutated UM was accompanied by inhibition of Erk1/2 phosphorylation, NF-κB, decreased expression of cyclin D1, survivin, Bcl-xL and XIAP, and increased expression of cyclin-dependent kinase inhibitor p27
INTRODUCTION
Uveal melanoma (UM) is the most common primary intraocular malignant tumor in adults, with an incidence of seven cases per million annually (1) . Approximately half of UM patients develop metastases to the liver within 15 years of initial diagnosis. With no effective treatment modality available the median survival time of UM patients with metastasis is less than six months (2) .
The etiology of UM has not been fully understood. Mutations in the GNAQ gene have been identified in approximately 50% of UM and 83% blue naevi (3) (4) (5) . The GNAQ gene encodes for the α subunit of q class of heterotrimeric GTP binding proteins (G proteins) that are composed of three subunits (Gα, Gß, and Gγ) and transduce signals from 7-transmembrane G-protein coupled receptors (GPCRs) to intracellular cascades (6) .
Activation of GPCRs results in exchange of GDP for GTP on the Gα subunit, resulting in the dissociation of the GTP bound form of Gα from Gßγ. Both Gα and Gßγ can then activate downstream cellular signaling pathways. The signal is terminated when GTP is hydrolyzed to GDP by the intrinsic GTPase activity of the Gα subunit. The majority of GNAQ mutations occur at codon 209 within the GTPase catalytic domain, resulting in loss of the intrinsic GTPase activity and constitutively activation of GNAQ. Expression of mutated GNAQ results in melanocyte transformation and increased Erk1/2 phosphorylation, indicating that mutant GNAQ behaves as a dominant acting oncogene (4, 5) . Currently, there are no available therapies targeting GNAQ.
The protein kinase C (PKC) family is a widely expressed group of serine/threonine kinases comprising multiple isoforms that can be divided into three structurally and functionally distinct subgroups (7, 8) . These are the conventional PKCs for activation. PKCs regulate key biological processes including cell proliferation, apoptosis, differentiation, angiogenesis, tumor development, and chemoresistance (7, (9) (10) (11) (12) (13) (14) (15) . PKCs are involved in GNAQ mediated activation of the MAPK/Erk1/2 pathways (6, 16) . It has been known that GNAQ transduces signals from GPCRs to phospholipase Cβ (PLCβ) (6) . PLCβ enzymes catalyze the hydrolysis of phosphatidylinositol biphosphate to release inositol trisphosphate and DAG that function as second messengers propagating and amplifying the Gα-mediated signal through activation of PKCs. Active PKCs further activate Erk1/2 through the RAF/MAPK/Erk1/2 pathway(16). Using shRNA mediated downregulation of PKC isoforms β, ε, and θ we have recently shown that these isoforms are functionally important for GNAQ mutated UM cells (17) . The oncogenic properties of mutant GNAQ and the important PKC roles in GNAQ-mediated Erk1/2 activation and GNAQ mutated UM cells (4, 16) suggested that PKC may provide new opportunities for therapeutic intervention of UM carrying GNAQ mutations. To test this hypothesis, UM cells carrying wild type GNAQ or GNAQ mutated at codon 209 were treated with the PKC inhibitor AEB071 (sotrastaurin), a PKC inhibitor that has potent activity against classical and novel PKC isotypes (18) . AEB071 selectively inhibited the growth of UM cells harboring GNAQ mutations by targeting PKC/Erk1/2 and PKC/NF-κB pathways. (19) .
MATERIALS AND METHODS
UM cells were cultured in RPMI 1640 containing 10% FBS, 50 µg/ml penicillin, and 100 µg/ml streptomycin at 37 o C and 5% CO 2 . These cell lines were recently authenticated by short tandem repeat PCR analysis at Biosynthesis Inc. Human epidermal melanocytes were purchased from Lifeline Cell Technology (Walkersville, MD) and grown in the medium provided by the company.
Viability assay. Cells were seeded in 96-well plates at 2x10 3 cells/well and incubated over night followed by treatment with AEB071 (provided by Novartis) for three days. Cell viability was measured as previously described (17) .
Cell cycle analysis. Cells were collected by trypsinization and fixed in cold ethanol. After incubation with RNase A and PI, cell cycle distribution was determined by flow cytometry analysis (FACS).
Analysis of apoptosis.
Apoptotic cells were detected by Annexin V-FITC staining and FACS as described previously (17) . Compensation for AEB071 autofluorescence was performed.
Knockdown of PKC isotypes by shRNA. The constructs (pLKO.1-puro) containing shRNA target sequences for PKCα, PKCδ, or GFP were provided by DanaFarber Cancer Institute shRNA Core Facility. Lentivirus expressing PKC shRNA was produced as describe previously (17) . Cells were infected with virus for three days and cell viability was determined using MTS assay.
Immunoblotting. Preparation of whole cell lysates and immunoblotting have been described previously (19) . Antibodies against PKC isoforms were: PKCα (Cell (19, 20) . AEB071 at low micromolar concentrations significantly decreased viability of all three GNAQ mutated cell lines ( Figure 1C ). The IC 50 functionally important in UM cells harboring GNAQ mutations. We have previously found that PKC isoforms β, ε, and θ are functionally critical for GNAQ mutated UM cells (17) . These findings together suggest that AEB071 suppressed growth of GNAQ mutated UM cells via inhibition of multiple PKC isoforms. We have found that Erk1/2 inhibition decreased UM cell viability (19) . Therefore, AEB071 may exert its anti-proliferative effects in part through suppression of Erk1/2 activation in GNAQ mutated UM cells.
AEB071 selectively decreases
AEB071 selectively inhibits NF-κB activity in GNAQ mutated UM cells. PKC isoforms are involved in GPCR-mediated NF-κB activation (27) (28) (29) (30) . In most cells, NF-κB is present as a latent, inactive, IκB-bound complex in the cytoplasm. On activation, IκB 
is phosphorylated and targeted to degradation. The released NF-κB translocates into the nucleus where it drives the expression of its target genes (29) . It is well known that aberrant NF-κB activity promotes tumorigenesis and metastasis (31) . We next examined whether AEB071 altered NF-κB activity in UM cells. In the absence of AEB071, nuclear p65 (RelA) levels are more or less similar among wild type and mutant cell lines ( Figure   6A ). In contrast, in the presence of AEB071, nuclear p65 levels were significantly decreased in GNAQ mutated UM cells while they were minimally altered in wild type cells ( Figure 6A ). Consistent with this, reduced DNA binding activity of NF-κB was detected only in the nuclear extracts of GNAQ mutated cells exposed to AEB071 ( Figure   6B ). In agreement with decreased NF-κB activity, elevated IκBα levels were detected in AEB071-treated GNAQ mutated cells ( Figure 6C) . Besides, the secretion of IL-6, one of the target genes of NF-κB, was substantially inhibited by AEB071 in GNAQ mutated Omm1.3 cells but not GNAQ wild type C918 cells ( Figure 6D ). These findings together indicate that AEB071 selectively inhibited NF-κB activation in UM cells harboring GNAQ mutations. This notion is also in agreement with the selective downregulation of NF-κB target genes including survivin, Bcl-xL, XIAP and cyclin D1, by AEB071 in GNAQ mutated cells (Figures 2C and 3C ).
NF-κB activity is functionally important for UM cells. To determine whether
NF-κB activity is functionally important for UM cells, both GNAQ wild type and mutated UM cells were treated with an IKK1/2 inhibitor that possesses potent NF-κB inhibition activity (32) . This treatment resulted in the dramatic decrease in viability of both GNAQ wild type and mutant UM cell lines (Supplemental Figure S3 ). These findings suggest that NF-κB activity is critically important for UM cells and its 
DISCUSSION
There are currently no drugs available targeting the oncogenic GNAQ mutations that occur frequently in primary and metastatic UM. In the present study we describe the first small molecule inhibitor that selectively exhibits antiproliferative activity of UM cells harboring GNAQ mutations: the novel PKC inhibitor AEB071 reduced viability of GNAQ mutated UM cell lines, but had little effect on those carrying wild type GNAQ.
AEB071-induced growth inhibition is associated with reduced expression of PKC isoforms α, β, δ, ε and/or θ, accompanied by inhibition of Erk1/2 phosphorylation, and NF-κB activation. We have previously shown that PKCθ, PKCβ and PKCε are functionally important for GNAQ mutated UM cells and that inhibition of Erk1/2 by MEK1/2 inhibitors reduced UM cell viability (17) . Here, we demonstrate that PKCα, PKCδ and NF-κB are also functionally important for GNAQ mutated UM cells. Together, our findings suggest that AEB071 may selectively exert antiproliferative activity on GNAQ mutated UM cells via targeting the PKC/Erk1/2 and PKC/NF-κB pathways.
AEB071 induced growth suppression of GNAQ mutant cells is associated with
pronounced G1 arrest and induction of apoptosis. The molecular mechanisms for AEB071 induced G1 arrest involve altered expression of positive and negative regulators of transition through G1 phase of cell cycle, including cyclin D1 and p27 Kip1 (33, 34) .
AEB071 induced apoptosis is associated with decreased expression of antiapoptotic
proteins, yet the underlying molecular mechanisms remain to be revealed. 
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The PI3K/Akt and MAPK pathways are frequently activated in malignant tumors and are critical for cancer cell survival and proliferation (35) (36) (37) . Erk1/2 activation is common in UM and has been reported to play a crucial role in UM development (38, 39) . AEB071 inhibited Erk1/2 phosphorylation in GNAQ mutated but not GNAQ wild type UM cells, and had minimal impact on Akt phophorylation. Similarly, we have recently found that PKC inhibitor enzastaurin inhibits phosphorylation of Erk1/2 but not Akt in GNAQ mutated cell lines (17) , although enzastaurin has been reported to inhibit Akt phosphorylation but not Erk1/2 phosphorylation in other types of cancer cells (24, 26, 40) .
The inhibition of Erk1/2 phosphorylation is therefore likely a common mechanism for the anti-proliferative action of PKC inhibitors in GNAQ mutated UM cells. Further studies are needed to identify the PKC isoform(s) which are most crucial for Erk1/2 phosphorylation in GNAQ mutant UM, and whose inhibition by AEB071 leads to decreased Erk1/2 phosphorylation. PKCβII and PKCθ are among the candidates, because activation of these isoforms triggers several signaling pathways including MAPK (9, 13, 17, 41) , and siRNA downregulation of PKCβII decreased Erk1/2 phosphorylation in metastatic hepatocellular carcinoma cells (42) .
In addition to the PKC/Erk1/2 pathway, activation of many GPCRs can trigger the PKC/IKK/NF-κB pathway through G proteins, including GNAQ (27) (28) (29) (30) 43) .
Overexpression of mutant GNAQ(Q209L) leads to constitutive activation of NF-κB which is mediated by PKCδ and to a lesser extent PKCα and PKCε in HUVEC (27, 28 BRAF mutation that constitutively activates the MAPK and NF-κB pathways (19, 20, (44) (45) (46) . High c-Met expression has been found in C918 and Mel285 cells (47) and it has been reported that NF-κB can be activated by HGF/c-Met signaling (48, 49) .
Our data indicate that multiple PKC isoforms including α, β, δ, ε, and θ are suppressed by AEB071 in GNAQ mutated UM cells while only PKCα and PKCδ were affected in GNAQ wild type cells. The findings from shRNA knockdown studies confirmed the functional importance of PKCα and PKCδ in GNAQ-mutated UM cells.
Knockdown of these two PKC isoforms had no (PKCα) or little (PKCδ) affect on viability of GNAQ wild type cells, suggesting that these two PKC isoforms are less important in GNAQ wild type cells compared to GNAQ mutated cells. Similarly, our previous shRNA-mediated knockdown studies have found that PKCβ, PKCε and PKCθ are functionally more important for GNAQ-mutated than wild type UM cells (17) .
Together, these findings suggest that GNAQ mutated UM cells are more dependent on these PKC isoforms than GNAQ wild type cells, and that AEB071 exerts anti- 
proliferative action on GNAQ mutated cells via suppression of these PKC isoforms.
These findings also provide a plausible explanation for the differential response/sensitivity of GNAQ wild type and mutated UM cells to AEB071.
G-protein coupled receptors (GPCRs) have a pivotal role in many physiological functions and in multiple diseases, including tumorigenesis and metastasis of cancers (50) .
Frequent somatic mutations in GPCRs have been found in melanoma and mutations in GRM3, which is a glutamate receptor and a member of the metabolic GPCRs, activate the MAPK/ERK pathway and promote growth and migration of melanoma cells (51) .
Furthermore, overexpression of diverse GPCRs were found in number of primary and metastatic cancers including melanoma, breast, prostate, non-small cell lung cancer, gastric tumors, head and neck squamous cell carcinoma (HNSCC), and diffused large B cell lymphoma (52, 53) . Overexpression of G protein-coupled receptors in cancer cells: involvement in tumor progression. GPCRs can also influence cancer progression through crosstalk with growth factor receptors such as EGFR and IGF-1R, G-proteins (such as Gaq/11and Ga12/13), chemokines, Hedgehog and WNT signaling pathways, regulation of the apoptotic response and viral factors. Various GPCRs can be involved in cancer through activating NF-κB (50) . As more data linking GPCRs to cancer emerge, these receptors are attractive potential targets for tumor therapy. In particular, the GPCR-ERK and GPCR-NF-κB pathways could be valuable targets for innovative anticancer drug discovery.
We demonstrate that PKC inhibitor AEB071 (sotrastaurin) at low micromolar 
